Mitochondrial dependency in progression of acute myeloid leukemia

Mitochondrion

Volumn 21, Issue , 2015, Pages 41-48

  Basak, Nandini Pal ^a   Banerjee, Subrata ^a  

^a SAHA INSTITUTE OF NUCLEAR PHYSICS   (India)

Author keywords

Acute myeloid leukemia; Altered metabolism; Cellular stress; Drug targets; Mitochondria; Oxidative phosphorylation

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AGI 6780; ENZYME INHIBITOR; ETOMOXIR; RANOLAZINE; RETINOIC ACID; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; AUTOPHAGY; DISEASE COURSE; HUMAN; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TARGETING SIGNAL; MYELOID LEUKEMIA CELL LINE; OXIDATIVE PHOSPHORYLATION; PROMYELOCYTIC LEUKEMIA; REVIEW; SIGNAL TRANSDUCTION; ACUTE MYELOBLASTIC LEUKEMIA; CELL PROLIFERATION; ENERGY METABOLISM; METABOLISM; MITOCHONDRION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADENOSINE TRIPHOSPHATE; CELL PROLIFERATION; ENERGY METABOLISM; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOCHONDRIA;

EID: 84922373212     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2015.01.006     Document Type: Review

References (109)

1. Altman J.K., Szilard A., Goussetis D.J., Sassano A., Colamonici M., Gounaris E., Frankfurt O., Giles F.J., Eklund E.A., Beauchamp E.M., Platanias L.C. Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clin Cancer Res 2014, 20:2400-2409.
2. Andersen J.L., Kornbluth S. The tangled circuitry of metabolism and apoptosis. Mol Cell 2013, 49:399-410.
3. Bar-Peled L., Chantranupong L., Cherniack A.D., Chen W.W., Ottina K.A., Grabiner B.C., Spear E.D., Carter S.L., Meyerson M., Sabatini D.M. A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 2013, 340:1100-1106.
4. Basak N.P., Roy A., Banerjee S. Alteration of mitochondrial proteome due to activation of Notch1 signaling pathway. J Biol Chem. 2014, 289:7320-7334.
5. Bots M., Verbrugge I., Martin B.P., Salmon J.M., Ghisi M., Baker A., Stanley K., Shortt J., Ossenkoppele G.J., Zuber J., Rappaport A.R., Atadja P., Lowe S.W., Johnstone R.W. Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood 2014, 123:1341-1352.
6. Boultwood J., Fidler C., Mills K.I., Frodsham P.M., Kusec R., Gaiger A., Gale R.E., Linch D.C., Littlewood T.J., Moss P.A., Wainscoat J.S. Amplification of mitochondrial DNA in acute myeloid leukaemia. Br J Haematol 1996, 95:426-431.
7. Cai J., Jones D.P. Mitochondrial redox signaling during apoptosis. J Bioenerg Biomembr 1999, 31:327-334.
8. Canh Hiep N., Kinohira S., Furuyama K., Taketani S. Depletion of glutamine enhances sodium butyrate-induced erythroid differentiation of K562 cells. J Biochem 2012, 152:509-519.
9. Carracedo A., Cantley L.C., Pandolfi P.P. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 2013, 13:227-232.
10. Chatterjee A., Mambo E., Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene 2006, 25:4663-4674.
11. Chaturvedi A., Araujo Cruz M.M., Jyotsana N., Sharma A., Yun H., Gorlich K., Wichmann M., Schwarzer A., Preller M., Thol F., Meyer J., Haemmerle R., Struys E.A., Jansen E.E., Modlich U., Li Z., Sly L.M., Geffers R., Lindner R., Manstein D.J., Lehmann U., Krauter J., Ganser A., Heuser M. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013, 122:2877-2887.
12. Chen Z.X., Pervaiz S. Bcl-2 induces pro-oxidant state by engaging mitochondrial respiration in tumor cells. Cell Death Differ 2007, 14:1617-1627.
13. Chen W.L., Wang J.H., Zhao A.H., Xu X., Wang Y.H., Chen T.L., Li J.M., Mi J.Q., Zhu Y.M., Liu Y.F., Wang Y.Y., Jin J., Huang H., Wu D.P., Li Y., Yan X.J., Yan J.S., Li J.Y., Wang S., Huang X.J., Wang B.S., Chen Z., Chen S.J., Jia W. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood 2014, 124:1645-1654.
14. Chiarugi A., Dolle C., Felici R., Ziegler M. The NAD metabolome-a key determinant of cancer cell biology. Nat Rev Cancer 2012, 12:741-752.
15. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
16. DeBerardinis R.J., Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010, 29:313-324.
17. Del Poeta G., Bruno A., Del Principe M.I., Venditti A., Maurillo L., Buccisano F., Stasi R., Neri B., Luciano F., Siniscalchi A., de Fabritiis P., Amadori S. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Curr Cancer Drug Targets 2008, 8:207-222.
18. Ding W.X., Yin X.M. Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Chem 2012, 393:547-564.
19. Dodson M., Darley-Usmar V., Zhang J. Cellular metabolic and autophagic pathways: traffic control by redox signaling. Free Radic Biol Med 2013, 63:207-221.
20. Emadi A., Jun S.A., Tsukamoto T., Fathi A.T., Minden M.D., Dang C.V. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol 2014, 42:247-251.
21. Falkenberg M., Larsson N.G., Gustafsson C.M. DNA replication and transcription in mammalian mitochondria. Annu Rev Biochem 2007, 76:679-699.
22. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol 2011, 194:7-15.
23. Fujimura S., Suzumiya J., Nakamura K., Ono J. Effects of troglitazone on the growth and differentiation of hematopoietic cell lines. Int J Oncol 1998, 13:1263-1267.
24. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002, 2:683-693.
25. Green D.R., Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004, 305:626-629.
26. Hatzimichael E., Georgiou G., Benetatos L., Briasoulis E. Gene mutations and molecularly targeted therapies in acute myeloid leukemia. Am J Blood Res 2013, 3:29-51.
27. He L., Luo L., Proctor S.J., Middleton P.G., Blakely E.L., Taylor R.W., Turnbull D.M. Somatic mitochondrial DNA mutations in adult-onset leukaemia. Leukemia 2003, 17:2487-2491.
28. Herst P.M., Howman R.A., Neeson P.J., Berridge M.V., Ritchie D.S. The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome. J Leukoc Biol 2011, 89:51-55.
29. Hirase N., Yanase T., Mu Y., Muta K., Umemura T., Takayanagi R., Nawata H. Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology 1999, 57(Suppl. 2):17-26.
30. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., Wang Z.Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
31. Huang Y., Hou J.K., Chen T.T., Zhao X.Y., Yan Z.W., Zhang J., Yang J., Kogan S.C., Chen G.Q. PML-RARalpha enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway. Autophagy 2011, 7:1132-1144.
32. Isaacs J.S., Jung Y.J., Mole D.R., Lee S., Torres-Cabala C., Chung Y.L., Merino M., Trepel J., Zbar B., Toro J., Ratcliffe P.J., Linehan W.M., Neckers L. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005, 8:143-153.
33. Isakson P., Bjoras M., Boe S.O., Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood 2010, 116:2324-2331.
34. Ito K., Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol 2014, 15:243-256.
35. Jaras M., Ebert B.L. Power cut: inhibiting mitochondrial translation to target leukemia. Cancer Cell 2011, 20:555-556.
36. Jhas B., Sriskanthadevan S., Skrtic M., Sukhai M.A., Voisin V., Jitkova Y., Gronda M., Hurren R., Laister R.C., Bader G.D., Minden M.D., Schimmer A.D. Metabolic adaptation to chronic inhibition of mitochondrial protein synthesis in acute myeloid leukemia cells. PLoS One 2013, 8:e58367.
37. Kannan S., Sutphin R.M., Hall M.G., Golfman L.S., Fang W., Nolo R.M., Akers L.J., Hammitt R.A., McMurray J.S., Kornblau S.M., Melnick A.M., Figueroa M.E., Zweidler-McKay P.A. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med 2013, 210:321-337.
38. Kats L.M., Reschke M., Taulli R., Pozdnyakova O., Burgess K., Bhargava P., Straley K., Karnik R., Meissner A., Small D., Su S.M., Yen K., Zhang J., Pandolfi P.P. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 2014, 14:329-341.
39. Konopleva M., Elstner E., McQueen T.J., Tsao T., Sudarikov A., Hu W., Schober W.D., Wang R.Y., Chism D., Kornblau S.M., Younes A., Collins S.J., Koeffler H.P., Andreeff M. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 2004, 3:1249-1262.
40. Krause D.S., Van Etten R.A. Right on target: eradicating leukemic stem cells. Trends Mol Med 2007, 13:470-481.
41. Lagadinou E.D., Sach A., Callahan K., Rossi R.M., Neering S.J., Minhajuddin M., Ashton J.M., Pei S., Grose V., O'Dwyer K.M., Liesveld J.L., Brookes P.S., Becker M.W., Jordan C.T. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013, 12:329-341.
42. Lee J., Giordano S., Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J 2012, 441:523-540.
43. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
44. Li L., Chen Y., Gibson S.B. Starvation-induced autophagy is regulated by mitochondrial reactive oxygen species leading to AMPK activation. Cell Signal 2013, 25:50-65.
45. Lin T.C., Chen Y.R., Kensicki E., Li A.Y., Kong M., Li Y., Mohney R.P., Shen H.M., Stiles B., Mizushima N., Lin L.I., Ann D.K. Autophagy: resetting glutamine-dependent metabolism and oxygen consumption. Autophagy 2012, 8:1477-1493.
46. Lindsley J.E., Rutter J. Nutrient sensing and metabolic decisions. Comp Biochem Physiol B Biochem Mol Biol 2004, 139:543-559.
47. Lo-Coco F., Hasan S.K. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol 2014, 27:3-9.
48. Loos B., Engelbrecht A.M., Lockshin R.A., Klionsky D.J., Zakeri Z. The variability of autophagy and cell death susceptibility: unanswered questions. Autophagy 2013, 9:1270-1285.
49. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., Edwards C.R., Khanin R., Figueroa M.E., Melnick A., Wellen K.E., O'Rourke D.M., Berger S.L., Chan T.A., Levine R.L., Mellinghoff I.K., Thompson C.B. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
50. Ludin A., Gur-Cohen S., Golan K., Kaufmann K.B., Itkin T., Medaglia C., Lu X.J., Ledergor G., Kollet O., Lapidot T. Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment. Antioxid Redox Signal 2014, 21:1605-1619.
51. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., Koboldt D.C., Fulton R.S., Delehaunty K.D., McGrath S.D., Fulton L.A., Locke D.P., Magrini V.J., Abbott R.M., Vickery T.L., Reed J.S., Robinson J.S., Wylie T., Smith S.M., Carmichael L., Eldred J.M., Harris C.C., Walker J., Peck J.B., Du F., Dukes A.F., Sanderson G.E., Brummett A.M., Clark E., McMichael J.F., Meyer R.J., Schindler J.K., Pohl C.S., Wallis J.W., Shi X., Lin L., Schmidt H., Tang Y., Haipek C., Wiechert M.E., Ivy J.V., Kalicki J., Elliott G., Ries R.E., Payton J.E., Westervelt P., Tomasson M.H., Watson M.A., Baty J., Heath S., Shannon W.D., Nagarajan R., Link D.C., Walter M.J., Graubert T.A., DiPersio J.F., Wilson R.K., Ley T.J. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066.
52. Mason E.F., Rathmell J.C. Cell metabolism: an essential link between cell growth and apoptosis. Biochim Biophys Acta 2011, 1813:645-654.
53. Mates J.M., Segura J.A., Alonso F.J., Marquez J. Pathways from glutamine to apoptosis. Front Biosci 2006, 11:3164-3180.
54. Mortensen M., Soilleux E.J., Djordjevic G., Tripp R., Lutteropp M., Sadighi-Akha E., Stranks A.J., Glanville J., Knight S., Jacobsen S.E., Kranc K.R., Simon A.K. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med 2011, 208:455-467.
55. Munoz-Pinedo C., El Mjiyad N., Ricci J.E. Cancer metabolism: current perspectives and future directions. Cell Death Dis 2012, 3:e248.
56. Neupert W., Herrmann J.M. Translocation of proteins into mitochondria. Annu Rev Biochem 2007, 76:723-749.
57. Nowak D., Stewart D., Koeffler H.P. Differentiation therapy of leukemia: 3 decades of development. Blood 2009, 113:3655-3665.
58. Ochocki J.D., Simon M.C. Nutrient-sensing pathways and metabolic regulation in stem cells. J Cell Biol 2013, 203:23-33.
59. Oka S., Hsu C.P., Sadoshima J. Regulation of cell survival and death by pyridine nucleotides. Circ Res 2012, 111:611-627.
60. Paschka P., Schlenk R.F., Gaidzik V.I., Habdank M., Kronke J., Bullinger L., Spath D., Kayser S., Zucknick M., Gotze K., Horst H.A., Germing U., Dohner H., Dohner K. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28:3636-3643.
61. Patel J.P., Gonen M., Figueroa M.E., Fernandez H., Sun Z., Racevskis J., Van Vlierberghe P., Dolgalev I., Thomas S., Aminova O., Huberman K., Cheng J., Viale A., Socci N.D., Heguy A., Cherry A., Vance G., Higgins R.R., Ketterling R.P., Gallagher R.E., Litzow M., van den Brink M.R., Lazarus H.M., Rowe J.M., Luger S., Ferrando A., Paietta E., Tallman M.S., Melnick A., Abdel-Wahab O., Levine R.L. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
62. Pei S., Minhajuddin M., Callahan K.P., Balys M., Ashton J.M., Neering S.J., Lagadinou E.D., Corbett C., Ye H., Liesveld J.L., O'Dwyer K.M., Li Z., Shi L., Greninger P., Settleman J., Benes C., Hagen F.K., Munger J., Crooks P.A., Becker M.W., Jordan C.T. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem 2013, 288:33542-33558.
63. Petros J.A., Baumann A.K., Ruiz-Pesini E., Amin M.B., Sun C.Q., Hall J., Lim S., Issa M.M., Flanders W.D., Hosseini S.H., Marshall F.F., Wallace D.C. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A 2005, 102:719-724.
64. Pike L.S., Smift A.L., Croteau N.J., Ferrick D.A., Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta 2011, 1807:726-734.
65. Ren J.G., Seth P., Everett P., Clish C.B., Sukhatme V.P. Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2. PLoS One 2010, 5.
66. Renneville A., Roumier C., Biggio V., Nibourel O., Boissel N., Fenaux P., Preudhomme C. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008, 22:915-931.
67. Robak T., Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009, 31(Pt 2):2349-2370.
68. Russell R.C., Yuan H.X., Guan K.L. Autophagy regulation by nutrient signaling. Cell Res 2014, 24:42-57.
69. Sachs L. The control of hematopoiesis and leukemia: from basic biology to the clinic. Proc Natl Acad Sci U S A 1996, 93:4742-4749.
70. Samudio I., Harmancey R., Fiegl M., Kantarjian H., Konopleva M., Korchin B., Kaluarachchi K., Bornmann W., Duvvuri S., Taegtmeyer H., Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010, 120:142-156.
71. +-dependent malic enzyme activity and malate-dependent pyruvate formation are progression-linked in Morris hepatomas. J Biol Chem 1980, 255:3844-3848.
72. Scherz-Shouval R., Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem Sci 2011, 36:30-38.
73. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7:77-85.
74. Sharawat S.K., Bakhshi R., Vishnubhatla S., Bakhshi S. Mitochondrial D-loop variations in paediatric acute myeloid leukaemia: a potential prognostic marker. Br J Haematol 2009, 149:391-398.
75. Shlush L.I., Zandi S., Mitchell A., Chen W.C., Brandwein J.M., Gupta V., Kennedy J.A., Schimmer A.D., Schuh A.C., Yee K.W., McLeod J.L., Doedens M., Medeiros J.J., Marke R., Kim H.J., Lee K., McPherson J.D., Hudson T.J., Brown A.M., Yousif F., Trinh Q.M., Stein L.D., Minden M.D., Wang J.C., Dick J.E. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014, 506:328-333.
76. Silkjaer T., Norgaard J.M., Aggerholm A., Ebbesen L.H., Kjeldsen E., Hokland P., Nyvold C.G. Characterization and prognostic significance of mitochondrial DNA variations in acute myeloid leukemia. Eur J Haematol 2013, 90:385-396.
77. Simon H.U., Haj-Yehia A., Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000, 5:415-418.
78. Skrtic M., Sriskanthadevan S., Jhas B., Gebbia M., Wang X., Wang Z., Hurren R., Jitkova Y., Gronda M., Maclean N., Lai C.K., Eberhard Y., Bartoszko J., Spagnuolo P., Rutledge A.C., Datti A., Ketela T., Moffat J., Robinson B.H., Cameron J.H., Wrana J., Eaves C.J., Minden M.D., Wang J.C., Dick J.E., Humphries K., Nislow C., Giaever G., Schimmer A.D. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 2011, 20:674-688.
79. Strohecker A.M., Guo J.Y., Karsli-Uzunbas G., Price S.M., Chen G.J., Mathew R., McMahon M., White E. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov 2013, 3:1272-1285.
80. Sylvester J.E., Fischel-Ghodsian N., Mougey E.B., O'Brien T.W. Mitochondrial ribosomal proteins: candidate genes for mitochondrial disease. Genet Med 2004, 6:73-80.
81. Tamburini J., Green A.S., Bardet V., Chapuis N., Park S., Willems L., Uzunov M., Ifrah N., Dreyfus F., Lacombe C., Mayeux P., Bouscary D. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009, 114:1618-1627.
82. Testa U., Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica 2007, 92:81-94.
83. Tomita A., Kiyoi H., Naoe T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol 2013, 97:717-725.
84. Torgersen M.L., Engedal N., Boe S.O., Hokland P., Simonsen A. Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells. Blood 2013, 122:2467-2476.
85. Tsao T., Kornblau S., Safe S., Watt J.C., Ruvolo V., Chen W., Qiu Y., Coombes K.R., Ju Z., Abdelrahim M., Schober W., Ling X., Kardassis D., Meyer C., Schimmer A., Kantarjian H., Andreeff M., Konopleva M. Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res 2010, 70:4949-4960.
86. Turrens J.F. Mitochondrial formation of reactive oxygen species. J Physiol 2003, 552:335-344.
87. Vander Heiden M.G. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011, 10:671-684.
88. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., Harris N.L., Le Beau M.M., Hellstrom-Lindberg E., Tefferi A., Bloomfield C.D. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
89. Vaux D.L., Korsmeyer S.J. Cell death in development. Cell 1999, 96:245-254.
90. Wallace D.C. Mitochondria and cancer. Nat Rev Cancer 2012, 12:685-698.
91. Wang F., Travins J., DeLaBarre B., Penard-Lacronique V., Schalm S., Hansen E., Straley K., Kernytsky A., Liu W., Gliser C., Yang H., Gross S., Artin E., Saada V., Mylonas E., Quivoron C., Popovici-Muller J., Saunders J.O., Salituro F.G., Yan S., Murray S., Wei W., Gao Y., Dang L., Dorsch M., Agresta S., Schenkein D.P., Biller S.A., Su S.M., de Botton S., Yen K.E. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013, 340:622-626.
92. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
93. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., Cross J.R., Fantin V.R., Hedvat C.V., Perl A.E., Rabinowitz J.D., Carroll M., Su S.M., Sharp K.A., Levine R.L., Thompson C.B. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
94. Ward P.S., Lu C., Cross J.R., Abdel-Wahab O., Levine R.L., Schwartz G.K., Thompson C.B. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 2013, 288:3804-3815.
95. Waxman S. Differentiation therapy in acute myelogenous leukemia (non-APL). Leukemia 2000, 14:491-496.
96. Willems L., Jacque N., Jacquel A., Neveux N., Maciel T.T., Lambert M., Schmitt A., Poulain L., Green A.S., Uzunov M., Kosmider O., Radford-Weiss I., Moura I.C., Auberger P., Ifrah N., Bardet V., Chapuis N., Lacombe C., Mayeux P., Tamburini J., Bouscary D. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 2013, 122:3521-3532.
97. Wise D.R., Thompson C.B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010, 35:427-433.
98. Xiao X., Yang J., Li R., Liu S., Xu Y., Zheng W., Yi Y., Luo Y., Gong F., Peng H., Pei M., Deng M., Zhang G. Deregulation of mitochondrial ATPsyn-beta in acute myeloid leukemia cells and with increased drug resistance. PLoS One 2013, 8:e83610.
99. Xu R.H., Pelicano H., Zhou Y., Carew J.S., Feng L., Bhalla K.N., Keating M.J., Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005, 65:613-621.
100. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Xiao M.T., Liu L.X., Jiang W.Q., Liu J., Zhang J.Y., Wang B., Frye S., Zhang Y., Xu Y.H., Lei Q.Y., Guan K.L., Zhao S.M., Xiong Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
101. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
102. Yang Z., Klionsky D.J. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol 2010, 22:124-131.
103. Yang M., Soga T., Pollard P.J. Oncometabolites: linking altered metabolism with cancer. J Clin Invest 2013, 123:3652-3658.
104. Yao Y.G., Ogasawara Y., Kajigaya S., Molldrem J.J., Falcao R.P., Pintao M.C., McCoy J.P., Rizzatti E.G., Young N.S. Mitochondrial DNA sequence variation in single cells from leukemia patients. Blood 2007, 109:756-762.
105. Yi C.H., Pan H., Seebacher J., Jang I.H., Hyberts S.G., Heffron G.J., Vander Heiden M.G., Yang R., Li F., Locasale J.W., Sharfi H., Zhai B., Rodriguez-Mias R., Luithardt H., Cantley L.C., Daley G.Q., Asara J.M., Gygi S.P., Wagner G., Liu C.F., Yuan J. Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Cell 2011, 146:607-620.
106. Yousefi S., Simon H.U. Autophagy in cells of the blood. Biochim Biophys Acta 2009, 1793:1461-1464.
107. Zaugg K., Yao Y., Reilly P.T., Kannan K., Kiarash R., Mason J., Huang P., Sawyer S.K., Fuerth B., Faubert B., Kalliomaki T., Elia A., Luo X., Nadeem V., Bungard D., Yalavarthi S., Growney J.D., Wakeham A., Moolani Y., Silvester J., Ten A.Y., Bakker W., Tsuchihara K., Berger S.L., Hill R.P., Jones R.G., Tsao M., Robinson M.O., Thompson C.B., Pan G., Mak T.W. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 2011, 25:1041-1051.
108. Zhang C., Moore L.M., Li X., Yung W.K., Zhang W. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol 2013, 15:1114-1126.
109. Zhou F.L., Zhang W.G., Wei Y.C., Meng S., Bai G.G., Wang B.Y., Yang H.Y., Tian W., Meng X., Zhang H., Chen S.P. Involvement of oxidative stress in the relapse of acute myeloid leukemia. J Biol Chem 2010, 285:15010-15015.